...Pfizer and the Challenges of the Global Pharmaceutical Industry Case Study Introduction This report is to summarize the results of Pfizer’s challenges on global pharmaceutical industry and analyze driving factors of competition. I briefly give the industry definition describing the scope of the analysis. The paper has the following major goals: 1) To analyze the current situation, major competition challenges and the prospects of the pharmaceutical industry; 2) To assess Pfizer’s position as a major players of the global pharmaceutical industry and make a comparative analysis of other business practices and financial results using the VRIO method; 3) To recommend Kindler opportunities for further strengthening of their positions by conducting Porter 5 forces. Pharmaceutical Industry Overview Historically, the pharmaceutical industry has developed, produced and marketed one of the most profitable and high margin drugs for many years. This industry has gone through substantial changes in the last few decade and pharmaceutical firms face major challenges, including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic drug substitution, international competitors, and complex public policy issues. Competition Challenges and Prospects A firm must develop a product-market diversification strategy otherwise it may face substantial setbacks once the product loses momentum. It’s important...
Words: 582 - Pages: 3
...Productivity in the context of Pharmaceuticals industry Organization Behavior (MGT 251) 7/20/2014 The document is on Employee turnover and organizational productivity of Square Pharmaceuticals, discussing various condition of employee turnover rate and the effect of that on the productivity level. An Assignment on Employee turnover and organizational productivity in the context of pharmaceutical industry. Course Code: MGT-251 Course Title: Organizational Behavior Section: 3 Submitted by Glen Archan Karmakar 2012-2-10-061 Asif Zubair 2012-2-10-066 Sazzad Ahmed 2011-3-10-048 Clinton Peter Gomes 2012-2-10-062 Abdul Momen Noman 2012-1-10-112 Sabbir Newaz 2010-1-10-267 Submitted to Rumana Afroz (RUA) Senior Lecturer Department of Business Administration Date of submission July 20, 2014 Rumana Afroz (RUA) Senior Lecturer Department of Business Administration Subject: Submission of the Report on “Employee turnover and organizational productivityin the context of pharmaceutical industry”. Dear Madam, Here is the report on the observational study of employee turnover in the context of pharmaceutical industry that you asked us to conduct in July, 2014. While preparing the term paper, we have tried our best to privide all the necessary information that will give a vivid scenario of our work on the topic mentioned above. We have gathered all the information from the industry themselves and by ourselves...
Words: 5071 - Pages: 21
...union in 1800 added the Kingdom of Ireland to create the United Kingdom of Great Britain and Ireland. Introduction: The United Kingdom (official name United Kingdom of Great Britain and Northern Ireland) consists of four countries united under one monarch and government. The countries are England, Scotland, Wales and Northern Ireland. Each have a distinct culture and feel of their own with some in Northern Ireland wishing to split from the United Kingdom and join the Republic of Ireland, with which the UK shares its only land border. England has traditionally been the dominant nation within the UK has over 80 percent of the share of the total population. People in Scotland and Wales have proud national traditions and languages. Scottish Gaelic is mainly spoken in the north west of the country, by a small proportion of the population. Welsh has a much bigger number of people speaking the language and all public signs in Wales are displayed in both Welsh and English. Economy Of Uk: Statistical Data Economy of the United Kingdom | Canary Wharf business district in London | Rank | 7th (nominal) / 8th (PPP) (3rd and 2nd in Europe respectively) | Currency | Pound sterling (GBP) | Fiscal year | 6 April – 5 April | Trade organizations | EU, BCN, OECD and WTO | Statistics | GDP | $2.480 trillion (2011)[1] (nominal; 7th)$2.253 trillion (2011)[2] (PPP; 8th) | GDP growth | 1.0% in Q3, 2012 (ONS) | GDP per...
Words: 3671 - Pages: 15
...Corporate Development Strategies Faculty 02 – Economics and Business Administration Johann Wolfgang Goethe-University Frankfurt Industry analysis of the pharmaceutical industry Written assignment Submitted by: Heiko Kreuz, 4897736, s5706079@stud.uni-frankfurt.de Janine Seelinger, 4896818, s1010710@stud.uni-frankfurt.de Dana Winkler, 4497800, s1099437@stud.uni-frankfurt.de Supervisor: Prof. Dr. Lars Schweizer November 6, 2015 Table of contents 1 Introduction...........................................................................................................................1 2 Theoretical framework of Porter’s Five Forces ........................................................1 3 Industry analysis by means of Porter’s Five Forces ................................................2 3.1 Competitive rivalry ................................................................................................... 2 3.2 Bargaining power of suppliers.................................................................................. 2 3.3 Bargaining power of buyers ..................................................................................... 2 3.4 Threat of substitutes ................................................................................................. 3 3.5 Threat of new entrants .............................................................................................. 3 3.6 The regulators ............................
Words: 1934 - Pages: 8
...conglomerates in Bangladesh. Square Pharmaceuticals Ltd., the flagship company, is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and is now on its way to becoming a high performance global player. SQUARE today is more than just an organization, it is an institute. In a career spanning across four and half decades it has pioneered the development of the local business in fields as diverse as Pharmaceuticals, Toiletries, Garments, Textile, Information Technology, Health Products, Food Products, Hospital, etc. With an average Annual turnover of over US$ 200 million and a workforce of about 3500 the SQUARE Group is a true icon of the Bangladesh business sector. Vision satement We view business as a means to the material and social wellbeing of the investors, employees and the society at large, leading to accretion of wealth through financial and moral gains as a part of the process of the human civilization. Mission statement Our Mission is to produce and provide quality & innovative healthcare relief for people, maintain stringently ethical standard in business operation also ensuring benefit to the shareholders, stakeholders and the society at large. Chapter B: Company Profile History of Square Group 1958 : | Debut of Square Pharma as a Partnership Firm. | 1964 : | Converted into a Private Limited Company. | 1974 : | Technical Collaboration with Janssen Pharmaceutical, Belgium, a subsidiary of...
Words: 5298 - Pages: 22
...GlaxoSmithKline company profile Francis Weyzig Amsterdam, October 2004 Summary Business description GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical corporations that discovers, develops, manufactures and markets branded human health products. Headquarters: UK, with additional operational headquarters in the USA Global presence: about 160 countries Primary markets: USA, France, Germany, UK, Italy and Japan Employees: approximately 103,000 GSK key figures for 2003 (in £ million) Sales 21,441 Materials and production costs 4,188 Marketing and administration 7,563 R&D expenditures 2,770 Operating income 6,920 Net profit 4,765 GSK has two main business divisions, pharmaceuticals and consumer healthcare. This profile deals with the pharmaceuticals division, which generates 85% of GSK’s sales. The five largest selling GSK products are Seretide/Advair for asthma and Chronic Obstructive Pulmonary Disease (COPD); Paxil/Seroxat and Wellbutrin, both antidepression drugs; Avandia/Avadamet for type 2 diabetes; and the antibiotic Augmentin. Each of these drugs generated above £800 million of sales in 2003. GSK produces a broad range of products of special importance to developing countries, including: Anti-malaria drugs Zentel (albendazole), for de-worming and the prevention of lymphatic filariasis Pentosam, against leishmaniasis Anti-retrovirals (ARVs) for the treatment of HIV/AIDS Tuberculosis drugs Vaccines for developing countries Corporate...
Words: 18642 - Pages: 75
...Project Presentation on Dr Reddy’s Laboratories Group 4: Abhishek Aggrawal Anik Bairagi Nishant Sawan Kumar Varun Saini 1 0911074 0911079 0911109 0911127 0911138 Global Pharmaceutical Market - Overview The increasing generics share and shift of the industry towards emerging markets is causing margin pressure on global pharma players and forcing them to invest in these new markets Global Pharmaceutical Market The pharmaceutical market was $ 820Bn in Other Patented 86% 83% 81% 79% 2009, growing at a CAGR of 9% over 200309 Generics is growing at double the rate of the Generics 2004 2006 2008 2010E total industry (18% CAGR), while Patented drugs market is growing at 7% India 1% Geographical Market Share Middle Africa 1% East 1% CIS 2% Others 12% US 42% Top 10 countries account for 73% of sales US accounts for 42% of the world sales While the US sales are growing at only 1-2% CAGR, growth in emerging markets is over 10% Latin America 6% South East and East Asia 6% EU 29% Source: Centrum Research Report on Pharma Industry 2009; 2 Key Growth Drivers for Global Pharmaceutical Market 1 Sluggish Growth in Mature Markets Economic slowdown leading to reduced healthcare spending Top brands’ patent expiries and very few new product launches Decentralization of government healthcare budgets. High healthcare expenditure by government 2 Faster Growth in Emerging Markets Broader public and private...
Words: 3256 - Pages: 14
...queries and feedback regarding this report. Yours truly, Mohammad Nakibur Rahman Roll: 55, Batch: 43D Wazedur Rahman Roll: 143, Batch: 46D i Table of Contents Executive Summary ....................................................................... iii 1. Introduction ............................................................................. 1 1.1 1.2 Objective ................................................................................................................................. 1 Scope ....................................................................................................................................... 1 1.3 Company Overview ....................................................................................................................... 1 1.4 Industry Overview ................................................................................................................... 2 2. Methodology...
Words: 3508 - Pages: 15
...capital budgeting technique in evaluating their potential projects especially in large R&D projects. The company mainly uses IRR. It uses sophisticated methods to project future cash flows. The company also uses scenario analysis to incorporate risk and for some very complex projects, it uses simulation analysis with the help of parent company in UK. However, Reckitt Benckiser Bangladesh Ltd is a well established company and it does not take large projects very often. Those capital budgeting techniques are normally used in evaluating large projects and in case of acquisition of an existing company. Company Overview Company Profile Reckitt Benckiser is a world leader in FMCG household, health and personal care. In Bangladesh it has started its journey as Reckitt Benckiser (Bangladesh) Ltd. The Company was listed in DSE in 1986 and in CSE in 1995 as a pharmaceuticals and chemical company. Currently, Reckitt Benckiser (Bangladesh) Ltd is a leading player in the FMCG market of Bangladesh with a focus on Health, Hygiene & Home. RB is involved in the business of manufacturing and marketing Household, Toiletries and Pharmaceuticals items. The company’s product array includes brands like Disprin, Dettol, Harpic, Mortein, Moov, Veet etc. Its strong achievement and entrepreneurial focused culture is renowned for giving employees unparalleled ownership of projects and decisions and where international mobility is encouraged. RB's an organization where driven people thrive. Financial...
Words: 2325 - Pages: 10
...Autumn Internship Report, Sep – Nov 2010 Research related work Research report preparation on the Nutraceuticals Sector Objective – Nutraceuticals are substances that offer nutrition beyond standard diet and include both fortified foods and beverages marketed by FMCG companies as well as dietary supplements that are mainly sold by pharmaceutical companies. Nutraceuticals is an emerging sector in India, and o3 Capital is looking at active participation in this space going forward. o3 Capital has a strong focus on research and such sector reports are often used to showcase the company’s capabilities to both potential client as well as investors. The main objective of this assignment was to prepare a comprehensive report on the sector that can eventually be used as part of client pitches and investor documents. The project also involved preparing brief profiles of key players in the sector to facilitate future business development activities in this space, and compilation of major global transactions in order to analyse transaction metrics and potential Scope – Following was the broad scope of the report 1. Overview of the global nutraceuticals market covering 1.1. Market Size and Growth 1.2. Key Markets 2. Detailed section on the Indian Nutraceuticals market covering 2.1. Market Size and Growth 2.2. Key Segments 2.3. Drivers 2.4. Challenges 2.5. Emerging product categories 3. Comparables Analysis and Investment Activity 3.1. Global Comparables 3.2. Global M&A Transaction...
Words: 9552 - Pages: 39
...CHAPTER 01: COMPANY OVERVIEW 3 1.1 Introduction 3 1.2 Basic Information and Chronology since Inception 4 1.3 Vision 5 1.4 Mission 5 1.5 Objective 5 1.6 Corporate Focus 5 1.7 Management Philosophy 5 CHAPTER 02: INDUSTRY ANALYSIS 7 2.1 Rivalry among existing firms 7 2.2 Threat of entry of new firms 9 2.3 Threat of Substitute products or Services 10 2.4 Bargaining power of suppliers 10 2.5 Bargaining power of buyers 11 CHAPTER 03: COMPANY ANALYSIS 13 3.1 SWOT ANALYSIS 13 3.1.1 STRENGTHS: 13 3.1.2 WEAKNESSES: 14 3.1.3 OPPORTUNITIES: 14 3.1.4 THREATS: 15 3.2 Competitive Strategy Analysis: 16 3.2.1 Advantage of SPL in using an Integrated Strategy: 17 3.2.2 Disadvantages of SPL in using an Integrated Strategy: 17 CHAPTER 01: COMPANY OVERVIEW 1.1 Introduction The flagship company of the Square group of industries, Square Pharmaceuticals Limited (SPL) is the largest pharmaceuticals company in Bangladesh. Founded in 1958 and headquartered in Dhaka, Bangladesh, SPL develops, manufactures and markets drugs for humans and the animal world. The company owns and operates modern pharmaceutical factories mainly in Bangladesh and also has a separate division to operate a modern chemical factory which produces and sells basic chemical products. It also has divisions to produce and sell agrovet and pesticide products. It exports its products to Europe, Asia, Africa and South America. SQUARE Pharmaceuticals Limited (SPL) is the largest pharmaceutical company in Bangladesh...
Words: 3682 - Pages: 15
...Dr. Reddy’s Laboratories-Growing pain This case study is about Dr Reddy's Laboratories Ltd (DRL), a global pharmaceutical company. Established in 1984, DRL was the largest Indian pharmaceutical company with a net worth of Rs.58 billion in 2007. As a fully integrated pharmaceutical company, DRL provided affordable medicines through its three core businesses - Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products. Since 2008, however, the drug maker went through a very difficult phase. The acquisition of German generics company betapharm Arzneimittel GmbH (Betapharm) in 2006 backfired, sinking the company into its worst ever quarterly loss in the fiscal 2008-09. Pending lawsuits for alleged patent infringements prevented DRL from launching generic products in its biggest market, the US. Moreover the ban imposed by the US Food and Drug Administration (FDA) on products made at DRL's Mexico unit for violation of manufacturing practices seriously dented the company's image as a quality drug maker. The ban also affected the company's revenues from the US market. A string of accidents which broke out across at DRL's Indian manufacturing facilities brought its safety practices under question. In a bid to crack the generics market in the US, the company lost sight of the domestic market and could not come up with new products in the Indian markets unlike its competitors. As a result, the company lost its coveted position in the domestic market. All...
Words: 1901 - Pages: 8
...PHARMACEUTICAL INDUSTRY RESEARCH PAPER Submitted By RAKESHKUMAR PATEL NILAMBEN PATEL MONROE COLLEGE NOVEMBER 19, 2012 MG 620 RESEARCHES FOR STATISTICS Presented to DR. ANNE WALSH ABSTRACT The United States is the world’s largest market for pharmaceuticals and the world leader in biopharmaceutical research. U.S. firms conduct 80 percent of the world’s research and development in biotechnology and hold the intellectual property rights to most new medicines. In 2010, the pharmaceutical sector employed approximately 272,000 people (source: Bureau of Labor Statistics), and according to the Pharmaceutical Research and Manufacturers of America (Parma), those manufacturers spent $67.4 billion on research and development in 2010. The markets for biologics, over-the-counter (OTC) medicines, and generics show the most potential for growth and have become increasingly competitive. Biologics, valued at $67 billion in 2010 (source: IMS Health), account for a quarter of all new drugs in clinical trials or awaiting Food and Drug Administration approval. OTC market growth will be driven by a growing aging population and consumer trend to self-medication and the conversion of drugs from prescription to non-prescription or OTC status. Generic drug sales in the United States were valued at $78 billion in 2010 (source: IMS Health). The U.S. market is the world’s largest free-pricing market for pharmaceuticals and has a favorable patent...
Words: 3366 - Pages: 14
...between organisms and disease. Some of your duties could include preparing technical reports and research papers detailing your findings and making recommendations based on your research. You might also supervise lab workers and technicians and perform lab experiments for government health departments and physicians. A microbiologist is a scientist who studies the properties of fungi, algae, bacteria and other microscopic organisms. Areas of specialization include virology, immunology or bioinformatics. The following chart provides an overview about this career. Degree Required Bachelor's degree Field of Study Microbiology, biochemistry or cell biology BS Biology is the course needed to take Microbiology. Microbiology Training For over 80 years we have been training the food industry and we pride ourselves on the quality and content of our training portfolio. We offer a range of microbiology training to the food and drinks industry from standard courses on HACCP (RSPH), shelf-life and auditing to food microbiology and tailored confidential training. In partnership with Skill gate we have developed an online microbiology course that covers eight basic modules, tutor assessment and a multiple choice examination. Tailored training on-site is available and bespoke programmed are drawn up after consultation with the client. They may be purely microbiology focused or have an element of microbiology and other topics e.g. legislation, processing, sensory and consumer science...
Words: 600 - Pages: 3
...Pump & Valve Industry – Overview & Opportunities About Singhi Advisors Your Partners in Growth . . . Private & Confidential Singhi Advisors Advantage Singhi Two Decades of delivering Success… Full service Investment bank with strong capabilities in M&A, PE & India Entry Strategy Many Services…One Goal MERGERS & ACQUISITIONS INDIA ENTRY STRATEGY PRIVATE EQUITY One of the top ten Investment Bankers and winner of the M&A Atlas Awards – Deal of the Year 2011, ACQ Global Award 2009 for ‘Corporate and M&A Advisory firm of the year-India’ o Co po ate a d & dv so y o t e yea da Multi–dimensional focus, covering all major sectors and industries Current focus with mid market and growing Corporates, while having strong relationships with top business houses in the country E Experienced & S bl M i d Stable Management, l di leading a team of >35 f 35 professionals, 70% of the team averaging 6+ years with Singhi Strong relationship and confidence from existing clients with 60% repeat business and 80% strike rate Live relationship with >250 Corporates, resulting in >800 ve e at o s p w t 50 Co po ates, esu t g 800 completed assignments. CORPORATE RESTRUCTURING DEBT SYNDICATION CORPORATE ADVISORY Global Reach Exclusive Indian Member of “Mergers-Alliance”, a leading international network of independent Investment Banking Firms and Corporate Finance advisory firms offering seamless services on mid-market transactions With the successful closure of more than 90 transactions...
Words: 5831 - Pages: 24
